The University of British Columbia

T-cell immunotherapy specialist Tmunity Therapeutics Inc. hopes to develop the first drug for a rare pediatric cancer called diffuse intrinsic pontine glioma (DIPG) after licensing global rights to

AbCellera Biologics Inc. has been profitable from the day it began signing partnerships in 2015 with a platform for novel antibody therapeutics. Now, it is in the process of recording a fourth consec

AbCellera Secures $10m Series A Investment AbCellera Biologics Inc. raised $10m in its Series A financing round led by DCVC Bio, which adds 2 board seats. (Sep.) Founded in 2012 based on microfluidi

Shortly after arriving at University of California, San Diego as its director of commercialization, Ruben Dario Flores-Saaib initiated an “entrepreneurs in residence” program that in two years helpe